Joanna Davies
Rheumatology · Los Angeles, CANPI 1699746958
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.7% of the total across 513 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 16.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,724 and has fallen 97.6% since, to $65 in 2025.
Across 513 payments — averaging $17.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- Lilly USA, LLC$1K
- Novo Nordisk$1K
- AbbVie$740
- Johnson & Johnson$601
- GSK$397
- plus $4K from 27 others
What the payments were for
- Food & beverage$8,73498%
- Education$2062%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 72 | $1,428 |
| Lilly USA, LLC | 81 | $1,095 |
| Novo Nordisk | 71 | $1,048 |
| AbbVie | 32 | $740 |
| Johnson & Johnson | 34 | $601 |
| GSK | 27 | $397 |
| Bayer | 18 | $393 |
| Zealand Pharma US, Inc. | 34 | $340 |
| Insulet Corporation | 21 | $320 |
| Mallinckrodt Hospital Products Inc. | 14 | $307 |
| Boehringer Ingelheim | 12 | $307 |
| AstraZeneca(2 entities) | 14 | $287 |
| Mannkind Corporation | 14 | $261 |
| Xeris Pharmaceuticals, Inc. | 8 | $171 |
| E.r. Squibb & Sons, L.L.C. | 6 | $129 |
| Mallinckrodt Enterprises LLC | 8 | $129 |
| Corcept Therapeutics | 5 | $108 |
| Radius Health, Inc. | 4 | $98 |
| Pfizer | 4 | $89 |
| Amarin Pharma, Inc. | 4 | $87 |
| Merck | 5 | $85 |
| Abbott | 4 | $78 |
| Dexcom, Inc. | 4 | $77 |
| IBSA Pharma Inc. | 4 | $74 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $59 |
| BD | 2 | $50 |
| Novartis | 2 | $41 |
| Alvogen Inc | 1 | $28 |
| Esperion Therapeutics, Inc. | 1 | $27 |
| Fresenius Kabi USA, LLC | 1 | $27 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Exact Sciences | 1 | $19 |
| Dermira, Inc. | 1 | $17 |
How this compares
$8,940 in reported general payments places this provider in the 70th percentile of 808 rheumatology providers in California.
Other rheumatology in Los Angeles
- Haoling WengLos Angeles$562K
- Glenn EhresmannLos Angeles$450K
- Elizabeth VolkmannLos Angeles$400K
- Daniel ArkfeldLos Angeles$378K
- Maureen McMahonLos Angeles$374K
- Leanna WiseLos Angeles$286K
- Jon GilesLos Angeles$248K
- Christina Charles-SchoemanLos Angeles$231K
- Karina Marianne TorralbaLos Angeles$142K
- Thomas RomanoLos Angeles$131K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.